OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
its financial results for the quarter ended March 31, 2017. The
full text of such press release is furnished as Exhibit 99.1 to
this report.
| (d) |
Exhibits.
|
| 99.1 |
Press Release, dated April 26, 2017, issued by OpGen,
Inc. |
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name. OpGen, Inc. (NASDAQ:OPGN) Recent Trading Information
OpGen, Inc. (NASDAQ:OPGN) closed its last trading session down -0.01 at 1.11 with 353,909 shares trading hands.